Mus vs Palau: The number of people with susceptibility test result for rifampicin
Mus
100
in 2021
Palau
100
in 2021
Mus rank
1st
Palau rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Mus
- Palau
How they compare
Mus currently reports 100 against 100 in Palau, a difference of 0.
Across all 5 years both countries report, Palau has been ahead every year.
Mus ranks 1st and Palau ranks 2nd of 2 regions.
Head to head by decade
| Decade | Mus | Palau | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 100 | 100 | 0 | — |
| 2020s | 100 | 100 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Mus or Palau?
- Mus, at 100 against 100 in Palau as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Mus and Palau?
- 0, with Mus ahead.
- How many years of comparable data are there for Mus and Palau?
- 5 years are reported by both, from 2017 to 2021.
- How do Mus and Palau rank globally for the number of people with susceptibility test result for rifampicin?
- Mus ranks 1st and Palau ranks 2nd of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.